Background: The intra-erythrocytic development of the malarial parasite is dependent on active uptake of nutrients, including human serum albumin(HSA), into parasitized erythrocytes(pRBCs). We have designed HSA-based nanoparticles as a potential drugdelivery option for antimalarials. Methods: Artemether-loaded nanoparticles(AAN) were designed and antimalarial activity evaluated in-vitro/in-vivo using Plasmodium falciparum/Plasmodium berghei species, respectively. Results: Selective internalisation of AAN into Plasmodium-infected RBCs in preference to healthy erythrocytes was observed using confocal-imaging. In-vitro studies showed 50% dose reduction for AAN as compared to drug-only controls to achieve IC 50 levels of inhibition. The nanoparticles exhibited 2-fold higher peak drug concentrations in RBCs with antimalarial activity at 50% of therapeutic doses in P.bergei-infected mice. Conclusion: HSA-based nanoparticles offer safe and effective approach for selective targeting of antimalarial drugs.
Introduction
Malaria is a global health priority with more than 3 billion people at risk [1] . Effective treatment of malaria is hampered by the development and rapid spread of resistance to all known classes of antimalarials. Furthermore, the non-specific targeting of intracellular parasites result in high doses of therapeutic agents being used with higher incidence of related toxicities. Upon invasion by the malaria parasite, the host erythrocyte cell membrane undergoes major remodelling in structure, composition and function [2] . The intraerythrocytic parasites import nutrients for their development and export proteins and lipids into the host cell cytoplasm. This transportation occurs through New Permeability Pathways (NPPs), which selectively increases the permeability of the cell membrane of parasitized red blood cells (pRBCs) to a wide range of low molecular weight solutes [3] . An interconnected network of tubovesicular membranes (TVMs) is postulated to be responsible for the import of small molecules, whereas secretary cleft and lipid rafts may play a significant role in macromolecular transport in pRBCs [4] . Certain macromolecules like dextran, Protein A and IgG2 antibody are known to have direct access to the parasite through the "parasitophorous duct," a tubular membranous structure that extends between the parasitophorous vacuolar membrane and the erythrocytic membrane [5] [6] [7] . These changes are of interest for antimalarial chemotherapy, as possible routes for targeting parasiticidal drugs into pRBCs.
Nanocarrier-based systems are providing new and powerful opportunities for targeting malaria-infected erythrocytes for the treatment of the disease [8, 9] . The overall goal for effective antimalarial therapy is the achievement of high intra-cellular drug concentrations in pRBCs. This would require the drug to cross multiple membrane barriers to access the intraparasitic targets, including the host erythrocyte membrane (HEM), the parasitophorous vacuolar membrane, the parasite plasma membrane and the food vacuolar membrane or endoplasmic reticulum membrane [10] .
Human serum albumin (HSA) is a non-toxic, non-immunogenic, biocompatible and biodegradable protein and has been widely used to design nanoparticles for drug delivery, and includes the commercially available nanoparticle albumin-bound (nab) paclitaxel, Abraxane™ [11] . In addition, HSA, an endogenous transport protein with multiple drug binding sites can act as a versatile drug carrier and offer various possibilities of surface modification by appending ligands to modify pharmacokinetics, enhance stability, prolong circulation half-life, alter drug release or act as a targeting agent [12, 13] . Notably high specificity and affinity interaction of native serum albumin with the parasitized erythrocytes have been reported [14] . Significantly, biotin-labelled and radio-iodinated HSA when added in vitro to malaria parasite cultures exhibited uptake, access to the parasite membrane through a membrane network and degradation in the parasite [15] . We took advantage of these features to use HSA as a nano-carrier for targeting anti-malarial drugs to pRBCs. The use of HSA to prepare nanoparticles for antimalarial drugs is an adept concept for selective targeting to pRBCs.
Artemether (ATM), a fast acting blood schizonticide is used as the current first-line therapy for severe multi-drug resistant malaria [16] . However, a very short half-life and poor aqueous solubility limits the clinical efficacy of this drug [17] . Currently, an oil-based injectable formulation for intramuscular administration is available commercially. However, its use is limited due to its non-defined and erratic absorption. A suitable vehicle for intravenous delivery of ATM is urgently needed, especially for treating severe and cerebral malaria. HSA binds strongly to artemisinin and its derivatives through thiol and amino groups [18] , paving the path to the development of artemether-loaded HSA-based nanoparticles which will open up opportunity for intravenous administration of artemether.
The aim of the present research was to develop and characterize HSA-based artemether nanoparticles for parenteral delivery and investigate their antimalarial efficacy and selective targeting to pRBCs. These nanoparticles were fabricated systematically using Quality-byDesign (QbD) approach. The nanoparticles were characterized for morphology, particle size, polydispersity index (PI), zeta potential, differential scanning calorimetry (DSC), X-ray diffraction (XRD) and Fourier transform infrared spectroscopy (FTIR) analysis. Their antimalarial efficacy was evaluated in vitro and in vivo using Plasmodium falciparum and Plasmodium berghei species, respectively. Pharmacokinetic studies after single intravenous injection were carried out in parasitized mice model to determine intra-cellular drug concentration in the RBCs. Confocal microscopy imaging was used to examine the entry of these nanoparticles selectively in pRBC in preference to non-infected RBCs. To best of our knowledge this is the first report of selective targeting of pRBCs using HSA based nanoparticles.
Experimental

Materials
Artemether was obtained as a gift sample from V. S. Internationals. HSA (Alburel) was purchased from Lifeline Pharmaceuticals, India. Absolute ethanol and polysorbate 80 were purchased from S. D. Fine chemicals Ltd. India. Trehalose was gift sample from Signet Chemicals, India. SYBR Green, hypoxanthine, gentamycin, formaldehyde solution, albumin bovine serum fraction V and 4′6-diamino-2-phenylindole were procured from Sigma Aldrich, UK. Dextrose anhydrous, was sourced from Fisher Scientific, UK and Hepes medium was from Gibco, Life Technologies, UK. All solvents and chemicals used were of analytical grade.
In vitro culture of Plasmodium
Plasmodiun falciparum parasites (strain 3D7 and K1) were grown in O+ve human RBCs in RPMI 1640 [+] L-glutamine, [+] Hepes medium supplemented with 5 mg/L albumin bovine serum fraction V, 50 mg/L hypoxanthine, 5 ml/L of 40% glucose and 50 mg/L of gentamycin (in PBS) in accordance with Read and Hyde [19] . Continuous culture of parasites at 5% haematocrit was carried out in 25 or 12.5 cm 2 flasks, in final culture volumes of 10 ml and 5 ml respectively with sub culturing at 48 and 72h intervals. Synchronization of parasite stages was achieved by adding sorbitol solution (5% w/v in distilled water filtered through a 0.22 µm filter) to the parasite pellet with a 5 min incubation. The culture was centrifuged at 3,000 rpm for 5 minutes and the supernatant discarded. The pellet was washed three times in complete RPMI prior to re-suspension at the appropriate haematocrit. Preliminary estimation of parasitaemia was carried out using Giemsa-stained thin blood smears. Culture flasks were gassed with a 5% CO 2 , 5% O 2 , 90% N 2 air mixture (BOC Limited, UK) and incubated at 37°C (Leec 190 CO 2 , Leec Limited, UK).
In vivo culture of Plasmodium
The P. berghei ANKA strain was used for in vivo evaluation of antimalarial activity. The strain is well characterised with high mortality in mice. The parasites kept in liquid nitrogen were thawed (at 37 °C) and parasitic culture was maintained in live mice through serial blood in accordance with guidelines on animal use and care and followed internationally accepted principles for laboratory animal use and care. Swiss albino mice of either sex aged 9-10 weeks and weighing 22-27g were used for the experiment. The animals were quarantined at a temperature of 22±3 0 C and 65% relative humidity and were fed a standard pelleted diet and provided with clean drinking water, throughout the experiment.
Development of artemether-loaded HSA nanoparticles
Artemether-loaded HSA nanoparticles (AAN) were prepared using the desolvation technique [20] [21] [22] followed by high-pressure homogenization. Briefly, HSA (Alburel) was diluted with water to obtain the desired concentration (2% w/v) and pH was maintained at neutral. The drug was dissolved in a mixture of ethanol (40% v/v) and polysorbate 80 (3%w/v), which was slowly injected in the protein solution. The dispersion was cross-linked by heating and homogenised in a high-pressure homogeniser (Niro Saovi Panda Plus). The nanoparticles thus obtained were lyophilised in presence of trehalose as cryoprotectant in a freeze dryer (Martin Christ Epsilon 2-4LSC). A 48 hour cycle was divided into three phases of 6, 18 and 24 hours for the stages of freezing, main drying and final drying, respectively (Table S1 ). Blank nanoparticles (BAN) were prepared using exactly the same protocol without addition of any drug. Rhodamine B (2.5µg) was covalently bound to AAN (1 ml)
hydroxysulfo-succinimide (sulfo-NHS) reaction with incubation at room temperature for 3 h to prepare rhodamine labelled nanoparticles [23, 24] . The labelled nanoparticles were subjected to dialysis against deionized water to remove any excess dye. Briefly 1 ml Rhodamine B tagged nanoparticles were put in dialysis membrane (3K MWCO) bag and suspended in beaker filled with 1000ml deionised water with continuous magnetic stirring for 1 h.
Systematic optimization of the formulation was carried out using the QbD approach [25] .
The Ishikawa diagram was used to determine the critical quality attributes (CQA) of the entire process (Fig 1) . The method was optimised for materials, process and environment related factors (Table 1) to correct the CQAs during the development. Apart from conventional optimisation with one factor at a time, two 3 2 factorial designs (9 runs each) were applied to optimise the material related parameters. Design I investigated the effect of HSA (at three levels; 1,2 and 3% w/v) and solvent concentration (at three levels; 20,30 and 40% v/v) and design II investigated the effect of HSA (at three levels; 1,2 and 3% w/v) and surfactant concentration (at three levels; 3, 5 and 7% w/v) on the particle size of the nanoparticles ( 
Characterisation of artemether-loaded HSA nanoparticles
Particle size and Polydispersity index
AAN was characterised for mean particle size and PI using photon correlation spectroscopy (PCS) technique employing N5 Beckman particle size analyser Inc., USA. All measurements were carried out at a fixed angle of 90 0 at 20 0 C using double distilled water as dispersant. The averaged values three measurements are presented.
Morphology
The microstructures of AAN particles were observed using transmission electron microscope (TEM) (Philips CM 200). Initially, sample diluted with double-distilled water was deposited on film-coated copper grids and allowed to dry overnight at room temperature.
The dried samples were visualized under TEM. Size and morphology of lyophilised nanoparticles were examined using a field emission scanning electron microscope (SEM) (Model JEOL JSM-7600F). AAN particles were first coated in gold to minimize the effect of heat during high power magnification.
Differential Scanning Calorimetry (DSC)
DSC measurements on ATM, HSA and AAN were performed using a Q200 TA instrument (New Castle, Delaware, USA). The heating runs were performed from 30°C to 200°C at 10.0°C/min. An empty aluminium pan was used as a reference.
Fourier Transform Infrared (FT-IR) spectroscopy
The interaction between the drug and carrier and the encapsulation of drug was evaluated using FT-IR spectroscopy using JASCO FTIR 5300 Spectrometer with TGS detector (MD, USA) over the scanning wavelength range of 4000 -400 cm-1. Potassium bromide disc method was employed to obtain FT-IR spectrums of AAN as well as the individual components.
X-ray Diffraction (XRD) Studies
XRD studies of ATM and AAN were performed using Philips Expertpro MPD diffractrometer (PAN analytical Inc. Germany) with resolution of 0.001 A 0 . The samples were radiated using a Cu target (λ = 1.54056 Å) and scanning angles ranged from 7 0 to 70 0 of 2θ.
Determination of entrapment efficiency
Entrapment efficiency was determined by separating the nanoparticles from aqueous dispersion by ultracentrifugation (30000g at 4 0 C for 1h) and the amount of free drug in the clear supernatant was analysed by UV-spectroscopy (UV 2450, Shimadzu, Japan) [16] . The 
In vitro Drug release
In vitro drug release study was performed in modified USP type II apparatus (Electrolab, India Pvt Ltd.). 3ml of AAN dispersion or reconstituted lyophilised AAN nanoparticles were enclosed within cellulose acetate dialysis bag (3K MWCO) and placed in 200 ml of phosphate buffer saline (pH 7.4): ethanol (50:50) as dissolution medium to maintain sink conditions The medium was continuously stirred at 100 rpm and maintained at 37±5 o C. 5ml
aliquots were withdrawn at predetermined time points (0.5, 1, 2, 4, 6, 8 and 24 h) and were replaced with the same volume of dissolution media. The concentration of drug released was analysed by UV Spectroscopy (UV 2450, Shimadzu, Japan) [17] .
In vitro erythrocyte toxicity study
Infection with P. falciparum result in erythrocyte rupture during its intra-erythrocytic life cycle causing haemolysis leading to anaemia in severe conditions [28] . For an antimalarial drug delivery system, it is important to have action targeted specifically on pRBCs with no harm to the uninfected erythrocytes. The in vitro erythrocyte toxicity study determines the toxicity potential of the system on the uninfected erythrocytes on intravenous administration.
The test was performed using varying dilutions of AAN in normal saline (1X, 10X and 100X). Polysorbate 80 (3% w/v) and Triton X 100 (2% w/v) in normal saline were used as reference and positive control respectively. 100µl of the prepared human RBCs were incubated with 900µl of the test solutions for 30 minutes. The reaction was stopped by addition of glutaraldehyde. The tubes were centrifuged to separate the debris and the supernatant was analysed for the haemolytic activity by measuring the absorbance at 540nm
by UV spectrophotometry (UV 2450, Shimadzu, Japan). The percent haemolysis was calculated by the formula:
% Haemolysis = Absorbance of sample -absorbance of control x 100 Absorbance of Triton X 100 -absorbance of control
In vitro susceptibility assay
Antimalarial drugs are maximally active on the mature trophozoite stage of parasite development. In vitro susceptibility has been correlated with the initial stage of the parasite, with isolates predominantly at the trophozoite stage having a twofold increase in IC50s compared to those of parasites predominantly at the ring stage [29, 30] . The in vitro antimalarial efficacy was therefore assessed using synchronised trophzoite stage cultures of P. falciparum (K1) parasite strains reported previously [31] . 
In vivo antimalarial efficacy in P. berghei infected mice
The lethal ANKA strain of P. berghei was used for the experiments [32]. Mice of either sex (average weight 25g) were infected by intraperitoneal inoculation of the parasite obtained from the donor mouse blood diluted with citrate phosphate dextrose containing approximately 5X10 7 -infected RBCs/ml. The mice were randomly divided into various groups (n = 5) ( Table 4) . Post-infection, the animals were treated with AAN aseptically reconstituted using sterile saline at two dose levels 0.624mg/day and 0.312 mg/day (equivalent to 100 and 50% of therapeutic dose of artemether) for four consecutive days. In lack of marketed intravenous artemether injection, artesunate (ARS), which has been previously employed for comparison in developmental antimalarial intravenous products [33, 34] , was used as reference. Larinate, marketed intravenous ARS injection, was reconstituted using the provided diluent under aseptic conditions and injected at same dose levels as AAN. Blank nanoparticles (BAN) were administered in volume equivalent to AAN containing 0.624mg of drug in AAN. On day 0, 1, 5, 7, 10, 14 and 21, day thin blood smears were prepared by collecting a drop of blood from the tail vein. The blood smears were airdried, fixed in methanol and stained with Giemsa stain. The smears were then washed, airdried and observed under the microscope using an oil immersion lens and parasitaemia was assessed. The study parameters involved (i) number of surviving animals from each group on day 30 (ii) mean percent parasitaemia over time (in days) for all groups. Data was expressed as mean±S.D. and assessed by unpaired t-test using the Graph-pad Instat Demo version. A difference of P < 0.05 was considered as significant.
Pharmacokinetics in P. berghei infected mice
The parasitized animals were divided into three groups of six mice per group. When animals reached parasitaemia of 50-60% the first group was administered AAN as single dose (35 mg/kg equivalent amount of artemether) intravenous injection. Artemether free drug being insoluble in water its solution was prepared by dissolving it in non clinical hydroaholic vehicle (ATM) [35] and administered intravenously to the second group while third group acted as control. At stipulated time interval of 10min, 30min, 1, 2, 4, 8, 10, and 24h, the animals were exposed to inhalation of anaesthetic ether and blood samples were withdrawn using retro-orbital puncture. ml/min. and detection wavelength was set at 210nm [37] . Each solution was injected in triplicate and mean peak areas were recorded for quantification for the drug.
Results
Development of artemether-loaded HSA nanoparticles
Basic methodology and all the essential material and process parameters required for development of nanoparticles were derived in reference to the Ishikawa Diagram (Fig 1) .
Risk identification and risk analysis of material, process and environment variables (Table 1) provided parameters for control strategy for the CQAs [25] . Optimization of the formulation was performed to reduce the risk of the CQAs to obtain a robust and reproducible formulation.
Concentration of HSA and Drug: HSA ratio was optimised based on the particle size and entrapment efficiency of the drug. Increasing the HSA concentration resulted in increase in particle size (Fig 2a) hence, 2% w/v concentration was found to be optimum showing negligible drug precipitation and lower particle size [20] . Incorporating ATM at drug: HSA ratio of 1:5 resulted in precipitation of drug while 1:20 ratio led to increase in particle size without added advantage in loading efficiency thus drug: HSA ratio of 1: 10 was found optimum (Table 3 ). ATM being highly water insoluble drug, incorporation of polysorbate 80 stabilised the nanoparticles with positive effect on drug entrapment (Fig 2c) [38, 39] .
Concentrations of HSA, ethanol and polysorbate 80 were further optimized using two 3 2 full factorial designs. The P-values of 0.0009 and 0.0274 indicated that the models were significant. Reducing the HSA concentration and increase in ethanol concentration resulted in smaller particle size (Fig 2d) [40] . The blue region in the response surface curve (Fig 2e) shows the area of lowest particle size, which could be achieved at the optimum HSA and surfactant concentration levels
Increasing the pH (>7) of the HSA solution prior to desolvation decreased the particle size of the nanoparticles (Fig 2b) , due to increased repulsion between the molecules preventing their aggregation. This observation is in good agreement with previously published literature [20, 41] . However ATM precipitated at higher pH, therefore it was important to maintain the pH of the HSA solution at 7 throughout the process. This could be explained by different HSA conformations at different pH values. The standard HSA conformation "N" is present at neutral pH. A change to the "B" conformation occurs above pH 8 which might have lower affinity to ATM [42] . Similar observations have been earlier reported [43] .
High-pressure homogenization was used to prepare HSA nanoparticles [44] . Effect of homogenization pressure and number of homogenisation cycles were seen to play an important role in determination of particle size. It was found that lower homogenisation pressures were sufficient to get the desired particle size (<100nm) and PI. Higher pressures led to increase in particle size [Supplementary data Table S2 ]. Though earlier reports have shown reduction in particle size with increase in homogenisation pressure for HSA nanoparticles, a minimum particle size of 222.2 nm could only be achieved at high homogenisation pressures [45] .
Freeze drying of nanoparticles
AAN was freeze-dried to get a free flowing stable product. Freeze-drying of AAN without cryoprotectant and with mannitol and lactose as cryoprotectants resulted in increased particles size and PI (Fig 3) [46] . Trehalose at 3% w/v concentration was found useful as cryoprotectant for lyophilisation of nanoparticles with neither a significant change in particle size (3a) nor in polydispersity index (Fig 3b) . Trehalose is known to preserve the HSA nanoparticle during freeze-drying as it forms amorphous glass, which is reported to interact with amorphous protein in the freeze-dried cake [47] .
Fluorescence spectroscopy for determination of binding of artemether to HSA
Fluorescence quenching of the single tryptophan residue in HSA was used to measure drug-binding affinity [48] . When HSA is excited at 280 nm, fluorescence intensity around 350 nm reflects changes of the microenvironment of tryptophan residue. Addition of ATM showed dynamic quenching of the fluorescence of HSA (Fig S4) and followed Stern Volume equation with Ksv of 1.755×10 4 L.mol -1 [26] . A strong decrease in the fluorescence intensity in the spectra of AAN nanoparticles (650a.u) was observed in comparison with the blank nanoparticles (900a.u) (Fig. 4) suggesting interaction of ATM and HSA. The quenching process also signifies the tertiary structural changes in HSA demonstrating binding of drug with HSA in the nanoparticulate formulation [49] .
Characterization of the nanoparticles
Mean particle size of AAN was found to be 66.1nm (PI 0.090) by PCS and was in confirmation to that obtained from TEM and SEM (Fig 5) of the freeze-dried product ( Fig S2) [50] . However, some sporadic weak peaks in AAN might indicate that ATM might not be not fully shielded by protein side chains and small amounts present on the surface. This is in accordance with our DSC results and consistent with a previous study [51] .
All the characteristic peaks of HSA observed in the FTIR were retained in the AAN indicating no chemical modification in the structure of the protein. The spectra of AAN revealed the characteristic peaks of ATM with almost negligible shifts from which it may be deduced that artemether is entrapped within the HSA matrix and that the chemical structure of artemether does not change after encapsulation (supplementary data Fig S 3 ). Similar FTIR spectroscopy results have been demonstrated for encapsulation of bioactive molecules into albumin nanoparticles [40, 52] .
In vitro release curves (Fig 5) of ATM from AAN showed an initial burst effect followed by slow release. This could be because of the different ways in which the drug is loaded in the nanoparticles: adsorption and entrapment [53] . Lyophilisation of nanoparticles did not have any effect on the drug release and was similar to that obtained from nanoparticles prior to lyophilisation.
In vitro erythrocyte toxicity study
ATM being practically insoluble, required polysorbate 80, a non-ionic surfactant to be incorporated in the formulation to improve its solubility and drug entrapment. Surfactants may cause damage to cell membranes of erythrocytes due to increases in membrane permeability [54] and therefore an in vitro erythrocyte toxicity test was carried out to evaluate biocompatibility of the nanoparticles [55] Triton-X-100 (positive control) showed 100% haemolysis of erythrocytes throughout the incubation period. Though polysorbate 80 solution (3% w/v) exhibited haemolysis of 75.89% after 30 min incubation, AAN containing 3% w/v polysorbate 80 showed an erythrocyte haemolysis rate of only 9.92% (Fig. 6) , demonstrating its safety. An earlier report by Joshi et. al., has shown very low erythrocyte haemolysis of NLC even at very high concentrations of surfactant [32] . This might be due to micelle formation of the surfactant at the nanoparticle and water interface, resulting in solubilisation of the drug and stabilisation of the entire system. Previous experiments have shown that a polysorbate 80 coating on the surface of HSA nanoparticles possess reduced toxicities and improved pharmacokinetic parameters of doxorubicin [56] . Clinically, upon administration, drugs injected intravenously are immediately diluted to a very large extent due to constant blood circulation and sink conditions provided by the body. To mimic in vivo conditions, diluted formulations were also tested for their haemolytic potential. AAN showed a haemolysis of 6.24% when diluted 10 times and 6.12% when diluted 100 times at the end of 30 minutes (Fig 5) .
In vitro susceptibility assay
Treatment of P. falciparum cultures with ATM and AAN demonstrated a dose-dependent
anti-parasitic effect while BAN, the HSA nanoparticle without any drug, failed to show any effect ( Fig. 7 ) [57] . AAN displayed optimal enhancement of anti-malarial activity in a concentration range of 3.13 to 12.5 nM. At concentrations that were too low to effectively kill the parasite, insignificant differences were observed in the efficacy of drug solution and 
Determination of cellular uptake of nanoparticles by confocal microscopy imaging
Nanoparticles attached on the surface of erythrocytes possess extended circulation time in the body [58] . Nano-sized particles (≤200 nm) have been shown to enter the RBC however; the translocation mechanism is not clear and remains controversial [59] Therefore, study was carried out to analyse actual entry of the nanoparticles into the plasmodium-infected erythrocytes.
DAPI staining helped in differentiating between parasitized and non-parasitized RBC in the co-cultures since DNA of the parasite is stained blue which is only present in the pRBC (Fig.8 ) [60] . Rhodamine-labelled AAN incubated with Plasmodium-infected RBCs showed time-dependent uptake selectively by pRBCs as evident by co-located red fluorescence in DAPI stained cells. (Fig 8) . The uptake starting at as early as 5 minutes of incubation and the fluorescence was found to persist till the rupture of pRBC. The uptake of nanoparticles was confirmed by Z-stacking of the confocal images which showed presence of florescence due AAN in various sections of the pRBCs (Fig S5) . All the confocal images confirmed that nanoparticles do not penetrate the normal non-infected RBCs as was evident by absence of red florescence of rhodamine-labelled nanoparticles in these cells (Fig 8) .
In vivo antimalarial efficacy in P. berghei infected mice
Nanostructured lipid carrier [32] and lipid nanoparticles [61] of artemether have shown improved antimalarial activity in P. berghei model. Peter's four-day suppressive test was performed on AAN at two dose levels viz, 100 and 50% of therapeutic dose of the drug using P. berghei-infected Swiss albino mice. Due to absence of any intravenous injection for artemether, Larinate (artesunate injection), which is administered as intravenous injection was used as the reference.
The control group showed highest parasitemia at all-time intervals with maximum of 72.13% on day 10 with all mice found to be dead after 10th day. As compared to the control group, all the other groups showed reduction in the parasitemia during the course of study (p < 0.001), analysed by one-way ANOVA followed by Tukey's multiple comparison test.
Marketed formulation showed reduction in parasitemia (23.46%, day 21) as compared to control at 100% dose level, however the reduction in parasitaemia was much less (46.34%, day 21) and the survival rate of animals was reduced to half (Table 4) when the dose was reduced to 50%. Parasitaemia with AAN was found to be 13.21% at 100% dose and 13.71%
at 50% dose level at the end of 21st day of the experiment. AAN showed significantly less (p<0.001) parasitaemia as compared to marketed intravenous injection of artesunate at both the dose levels (Fig 9) . Blank nanoparticles showed reduction in the parasitaemia (30.48%) on 21st day as compared to the control. Previously Blank NLC (placebo vehicle) has also shown reduction in the parasitaemia [32] . The reason for the activity is not known since none of the excipients is known to have any antimalarial activity. The surfactant used in the formula might by responsible for the parasitic cell haemolysis due to increased permeability of the parasitized cell, which might have resulted in the activity. Interestingly albumin has been reported to reduce mortality when given as adjunct therapy in children with severe malaria (62).
Pharmacokinetics and erythrocyte drug concentration in P. berghei-infected mice
AAN showed higher drug concentrations in the erythrocytes and deliver their payload to the target cell more efficiently than the molecular drug solution. AAN showed two times higher peak drug concentration in the RBCs as compared to ATM solution (Fig 10a) . This is consistent with the results obtained in in-vitro P. falciparum studies, which showed increased intracellular uptake by pRBCs and higher inhibition of parasitaemia by AAN. This is also reflected by higher AUC 0 24 (p< 0.05) in the RBCs after administration of AAN (1017.5±107µg.min/ml) as compared to ATM solution (554.5±68µg.min/ml)). After intravenous administration, AAN and ATM showed high initial plasma concentrations followed by constant decline with very low concentrations remaining at the end of 10h and no drug in plasma at 24h. AAN revealed lower drug levels in plasma as compared to ATM probably because of partitioning more into RBCs (Fig.  10  b) 
Discussion
Clinical management of severe and cerebral malaria remains a challenge with varying degrees of success even with parenteral administration of potent anti-malarial agents. Drug delivery strategies that can target the antimalarial drugs selectively to the pRBCs can potentially reduce drug exposure to non-target sites, delivering high drug concentrations to the infected cells and reducing the risk of drug resistance. In this study, we show HSA nanoparticles to be selectively taken up by pRBCs leading to higher local drug concentrations and improved antimalarial efficacy.
Robust HSA nanoparticles were developed using the QbD approach. An industrially feasible and scalable process of high-pressure homogenisation was used to fabricate the nanoparticles [44] . ATM being water insoluble is presently available as an oily intramuscular injection. HSA showed strong binding to artemether (Fig 4f) and with resultant physical linkages facilitated nanoparticle formation. Addition of polysorbate 80 (3% w/v) stabilised the nanoparticles and prevented drug precipitation, leading to formulation of an aqueous injection of ATM with high drug loading [39] . Addition of polysorbate 80 had no discernible adverse effect on the cell membrane of erythrocytes, as demonstrated by low haemolytic activity (<10%), which was further reduced on dilution (Fig 5) . The nanoparticles can be considered safe for intravenous administration.
It is important to control the size of the prepared nanoparticles because smaller sized particles improve the bioavailability, with increased ability to enter cells. It has been reported that only NLCs <400 nm diameter were taken up by pRBCs. [63] . In another study, it was determined that fluorescent latex beads >172 nm did not access intracellular parasites [7] . In our study we aimed to prepare nanoparticles having particle sizes less than 100 nm. HSA concentration critically affected the particle size and drug entrapment. While higher HSA concentrations led to increase in particle size, lower concentrations decreased the drug entrapment. The average size of the particles also decreased with increase in the percentage of added ethanol [40, 64] . In this context, the optimised nanoparticles with Drug:HSA ratio of 1:10 at 40% ethanol concentration as desolvating agent produced the smallest nanoparticles with highest drug loading (77.6%). Low homogenisation pressure 200 bar (10 cycles) followed by 5 cycles at 400 bar was sufficient to yield mean particle size of 66.1 nm and PI of 0.090. Higher homogenisation pressures resulted in a larger particle size. This can be explained as follows; the additional energy input resulted in higher kinetic energy of the particles with subsequent coalescence. Once the maximum dispersitivity has been reached additional energy put into the system cannot be used for further dispersion of nanoparticles.
The energy put in can only accelerate the velocity of the particles, giving them adequate kinetic energy to overcome the stabilization resulting in aggregation and increase in mean size [65] .
Since ATM is known to be moisture sensitive, drug freeze-drying was investigated to retain the stability of AAN. Freezing often induces many destabilizing stresses for nanoparticles. Formation of ice crystals that can mechanically destabilize nanoparticles and increased interaction due to enhanced nanoparticle concentration leading to aggregation or fusion are some of the phenomena observed during freeze drying [66] . Trehalose as an additive seems to provide sufficient protection from lyophilization of HSA protein, contributing to maintaining stability in the solid state [67] . Trehalose containing formulations were superior to mannitol and lactose, exhibiting minimal increases in nanoparticle size and PI following the freeze-drying procedure (Fig 3a,3b ) [68] .
The release of drug from AAN was characterised by a biphasic release pattern with an initial burst release (t50% -4.6h) followed by sustained drug release (t90% -25.3h) (Fig 5e) .
The initial fast release is attributed to the weakly interacted drug associated with surface of the nanoparticles. Subsequently, the entrapped ATM released from the core of the nanoparticles in a sustained manner due to the diffusion of drug across the albumin matrix, would provide the possibility of continual drug effect. A similar phenomenon was observed previously in albumin nanoparticles [69] [70] [71] . However the association of the drug with the carrier material in competition with other carriers such as plasma proteins, lipids, and cell membranes plays an important role for the performance in vivo [72] .
In [73, 74] . But contrary to this, uptake of ferritin claiming that Plasmodium-infected red cells are capable of endocytosis have been reported [75] . Many changes occur in the host cell membrane during intracellular malarial parasite development with extensive degradation of spectrin, allowing endocytosis in pRBCs [76, 77] . Parasites are capable of enhancing the permeability of cell membranes in the host through NPP [78,] and TVM [79] allowing nutrients access to the parasite. This increased permeability differs from the native transport systems of the normal erythrocyte [80, 81] . Membrane-impermeable macromolecules in the external medium have been shown to bypass the host cell cytosol to reach intracellular parasites [82, 83] . Though internalisation mechanisms remain to be elucidated, it is speculated that HSA nanoparticles would follow similar uptake pathways, as HSA which has been reported to have direct access through the parasitophorous duct [5, 6, 15] selective cellular uptake of nanoparticles by pRBCs as observed by confocal microscopy.
Conclusion
In conclusion, biodegradable artemether-loaded HSA-based nanoparticles were developed as an intravenous drug delivery system for the treatment of malaria. Robust formulation with reproducible particle size was successfully obtained employing the QbD approach. . In vitro studies using P. falciparum showed a 50% reduction in IC 50 shown significant potential to be used as a safe and effective drug delivery system for the treatment of malaria. As it permits intravenous administration and selective pRBC uptake, it can be a beneficial strategy in severe and cerebral malaria. 
